Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Bode

Showing results (531-540 of 589) with videos related to

Pageof 59
Sort By:
Diabetic Medicine : a Journal of the British Diabetic Association|May 29, 2013
Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trialB W Bode, J B Buse, M Fisher, et al.
Diabetes Care|June 8, 2015
Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 DiabetesArthur T Sands, Brian P Zambrowicz, Julio Rosenstock, et al.
Diabetes Technology & Therapeutics|July 11, 2018
Diabetes Technology Use Among Pregnant and Nonpregnant Women with T1D in the T1D ExchangeSarit Polsky, Mengdi Wu, Bruce W Bode, et al.
Nature|December 10, 1999
Crystal structures of the membrane-binding C2 domain of human coagulation factor VS Macedo-Ribeiro, W Bode, R Huber, et al.
Science (New York, N.Y.)|May 24, 2021
Structural basis of ribosomal frameshifting during translation of the SARS-CoV-2 RNA genomePramod R Bhatt, Alain Scaiola, Gary Loughran, et al.
Diabetes Care|March 31, 2017
Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1)David Russell-Jones, Bruce W Bode, Christophe De Block, et al.
Diabetes Technology & Therapeutics|January 26, 2024
Glycemic Outcomes Persist for up to 2 Years in Very Young Children with the Omnipod<sup>®</sup> 5 Automated Insulin Delivery SystemDaniel J DeSalvo, Bruce W Bode, Gregory P Forlenza, et al.
ACS Applied Materials & Interfaces|June 9, 2021
KAT Ligation for Rapid and Facile Covalent Attachment of Biomolecules to SurfacesAlessandro Fracassi, Ankita Ray, Nako Nakatsuka, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 16, 2002
The metabolism and excretion of galantamine in rats, dogs, and humansG S J Mannens, C A W Snel, J Hendrickx, et al.
Mayo Clinic Proceedings|September 6, 2016
New Insulin Delivery RecommendationsAnders H Frid, Gillian Kreugel, Giorgio Grassi, et al.
Pageof 59

Showing results (531-540 of 589) with videos related to

Sort By:
Pageof 59
Diabetic Medicine : a Journal of the British Diabetic Association|May 29, 2013
Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trialB W Bode, J B Buse, M Fisher, et al.
Diabetes Care|June 8, 2015
Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 DiabetesArthur T Sands, Brian P Zambrowicz, Julio Rosenstock, et al.
Diabetes Technology & Therapeutics|July 11, 2018
Diabetes Technology Use Among Pregnant and Nonpregnant Women with T1D in the T1D ExchangeSarit Polsky, Mengdi Wu, Bruce W Bode, et al.
Nature|December 10, 1999
Crystal structures of the membrane-binding C2 domain of human coagulation factor VS Macedo-Ribeiro, W Bode, R Huber, et al.
Science (New York, N.Y.)|May 24, 2021
Structural basis of ribosomal frameshifting during translation of the SARS-CoV-2 RNA genomePramod R Bhatt, Alain Scaiola, Gary Loughran, et al.
Diabetes Care|March 31, 2017
Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1)David Russell-Jones, Bruce W Bode, Christophe De Block, et al.
Diabetes Technology & Therapeutics|January 26, 2024
Glycemic Outcomes Persist for up to 2 Years in Very Young Children with the Omnipod<sup>®</sup> 5 Automated Insulin Delivery SystemDaniel J DeSalvo, Bruce W Bode, Gregory P Forlenza, et al.
ACS Applied Materials & Interfaces|June 9, 2021
KAT Ligation for Rapid and Facile Covalent Attachment of Biomolecules to SurfacesAlessandro Fracassi, Ankita Ray, Nako Nakatsuka, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 16, 2002
The metabolism and excretion of galantamine in rats, dogs, and humansG S J Mannens, C A W Snel, J Hendrickx, et al.
Mayo Clinic Proceedings|September 6, 2016
New Insulin Delivery RecommendationsAnders H Frid, Gillian Kreugel, Giorgio Grassi, et al.
Pageof 59